News

Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector

Jun 18, 2026 | News, Regulatory

It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma

Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1

Jun 17, 2026 | News, Research

The phase 3 results show improvements in daily function, cognition and nighttime sleep

Gilead’s New Drug Application for Yeztugo accepted by US FDA

Jun 16, 2026 | News, Regulatory

The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention

Ultomiris gets US FDA Priority Review for immunoglobulin A nephropathy treatment

Jun 15, 2026 | News, Regulatory

If approved, this would be the first C5 complement inhibitor available for this rare kidney disease

Novo Nordisk’s Wegovy approved as UK’s first daily GLP-1 weight loss pill

Jun 12, 2026 | News, Regulatory

The tablets will be available as a once-daily treatment, an alternative to weekly injections for adults with obesity, or overweight with a weight-related condition

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Jun 11, 2026 | News, Regulatory

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

Jun 10, 2026 | News, Regulatory

This new option for patients allows for as few as six maintenance injections per year

GSK to acquire biopharma Nuvalent for $10.6bn

Jun 9, 2026 | News, Research

Two of Nuvalent’s NSCLC therapies have received FDA Breakthrough Therapy and Orphan Drug Designations

CSL’s Privigen approved as measles treatment by European Commission

Jun 9, 2026 | News, Regulatory

Cases of measles have been rising in Europe since 2023

Roche and Nurix Therapeutics to partner in $2.3bn deal

Jun 8, 2026 | News, Research

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA

Jun 5, 2026 | News, Regulatory

In the study, there were improvements in motor function as well as a slowing of neurodegeneration

Alnylam and Inceptive agree on $2bn AI collaboration

Jun 4, 2026 | News, Research

The deal will assist accelerate the discovery of RNAi therapeutics

Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector

Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1

Gilead’s New Drug Application for Yeztugo accepted by US FDA

Ultomiris gets US FDA Priority Review for immunoglobulin A nephropathy treatment

Novo Nordisk’s Wegovy approved as UK’s first daily GLP-1 weight loss pill

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

GSK to acquire biopharma Nuvalent for $10.6bn

CSL’s Privigen approved as measles treatment by European Commission

Roche and Nurix Therapeutics to partner in $2.3bn deal

Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA

Alnylam and Inceptive agree on $2bn AI collaboration

Latest content

Latest intelligence

Quick links